Biofrontera Inc. BFRIW NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

32/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Biofrontera Inc. (BFRIW) has a negative trailing P/E of -1.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -91.36%, forward earnings yield 434.78%.

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -1.1); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -91.36%).
Forward P/E 0.2 — analysts expect a return to profitability with estimated EPS of $0.13 for FY2027.
Trailing Earnings Yield -91.36% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 434.78% as earnings recover.

Overall SharesGrow Score: 30/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

32/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

50/100

Debt-to-Equity & liquidity

→ Health

MOAT

50/100

→ Income

GROWTH

48/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — BFRIW

Valuation Multiples

P/E (TTM)-1.1

Forward P/E0.2

PEG RatioN/A

Forward PEG0.00

P/B Ratio1.10

P/S Ratio0.28

EV/EBITDA-1.1

Per Share Data

EPS (TTM)$-0.90

Forward EPS (Est.)$0.13

Book Value / Share$0.90

Revenue / Share$3.58

FCF / Share$-1.15

Yields & Fair Value

Earnings Yield-91.36%

Forward Earnings Yield434.78%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2019	-4.9	0.00	-1.77	2.04	-
2020	-4.7	-0.99	8.78	2.71	-
2021	-3.4	-0.03	11.34	5.34	-
2022	-30.3	0.31	0.81	0.68	-
2023	-0.2	0.00	0.89	0.13	-
2024	-0.3	0.00	1.36	0.16	-
2025	-0.6	0.01	0.55	0.14	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2019	$-18.09	$26.18M	$-10.98M	-41.9%
2020	$-18.94	$18.85M	$-10.99M	-58.3%
2021	$-44.10	$24.1M	$-37.71M	-156.5%
2022	$-0.61	$28.67M	$-640K	-2.2%
2023	$-13.02	$34.07M	$-20.13M	-59.1%
2024	$0.00	$37.3M	$-17.76M	-47.6%
2025	$-0.90	$41.71M	$-10.54M	-25.3%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.12	$-0.12 – $-0.11	$45.65M	$44.09M – $47.21M	1
2027	$0.13	$0.12 – $0.14	$54.7M	$52.83M – $56.57M	1
2028	$0.27	$0.26 – $0.28	$63.36M	$61.2M – $65.53M	1
2029	$0.39	$0.37 – $0.41	$80.08M	$77.35M – $82.81M	1